The board (the "Board") of directors (the "Directors") of Beijing Luzhu Biotechnology Co., Ltd. announced that the Company entered into a strategic cooperation framework agreement (the " Strategic Cooperation Framework Agreement") with Tianjin Ringpu Bio-Technology Co., Ltd. ("Tianjin Ringpu") on June 26, 2023. Pursuant to the Strategic Cooperation Framework Agreement, the Company and Tianjin Ringpu will jointly develop monoclonal antibody drugs and genetically engineered vaccines for pets ("Potential Pipeline Products"). The Company will provide R&D support to Tianjin Ringpu using its technical advantages in the human monoclonal antibody, protein and genetically engineered vaccine and other fields.

The Company will be responsible for the basic R&D and verification of products, while Tianjin Ringpu will be responsible for facilitating the process of clinical trials, registration, production and commercialization of the Potential Pipeline Products. The Company agreed Tianjin Ringpu to be its sole partner with respect to the development, registration, production and sales for the Potential Pipeline Products. The Directors are of the view that, riding on Tianjin Ringpu's experience in animal experiments, animal husbandry, veterinary science and technology and other aspects, the technical expertise of the Company in recombinant protein, monoclonal antibody and other fields could be further enhanced, and hence such arrangements as stipulated in the Strategic Cooperation Framework Agreement are in line with the Company's long-term development strategy and the interests of all shareholders of the Company.